After months of work under the radar, GlaxoSmithKline committed to entering the Zika R&D field, announcing on Thursday that it’s pairing with the National Institutes of Health in a project based at its new vaccine research hub in Rockville, MD.
{iframe}http://www.fiercepharma.com/pharma/gsk-enters-zika-vaccine-scene-nih-collaboration{/iframe}